Mitotane treatment for recurrent adrenocortical carcinoma following adrenalectomy

被引:0
|
作者
Garcia Dominguez, Paula [1 ]
Dibella, Andrea [1 ]
机构
[1] Southern Cty Vet specialists, Internal Med, Ringwood BH24 3JW, Hampshire, England
来源
VETERINARY RECORD CASE REPORTS | 2023年 / 11卷 / 04期
关键词
adrenalectomy; carcinoma; mitotane; PITUITARY-DEPENDENT HYPERADRENOCORTICISM; GLAND TUMORS; CANINE HYPOADRENOCORTICISM; SURGICAL-MANAGEMENT; DOGS; SURVIVAL;
D O I
10.1002/vrc2.739
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A dog was referred for investigation into polyuria and polydipsia. Investigations showed a right adrenal mass, adrenalectomy was performed, and histopathology reported a carcinoma with local invasion. Carboplatin was selected as an adjuvant chemotherapy. Initially, did not show signs of recurrence, but 9 months later the clinical signs recurred, and staging was consistent with recurrence of the carcinoma with local hepatic invasion. The mitotane ablative protocol was chosen. Our patient developed mineralocorticoid deficiency 60 days later, but never developed clinical signs of cortisol deficiency as it was started on prednisolone. Kintzer and Peterson reported that dogs with metastatic disease experienced poorer response to mitotane and shorter survival time. However, our patient responded very well, with no side effect and remission of all clinical signs. The patient is alive at time of writing this report, 10 months after starting mitotane and 22 months after diagnosis.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Adrenocortical Carcinoma: Surgery and Mitotane for Treatment and Steroid Profiles for Follow-up
    A. Khorram-Manesh
    H. Ahlman
    S. Jansson
    B. Wängberg
    O. Nilsson
    C.E. Jakobsson
    B. Eliasson
    S. Lindstedt
    L.E. Tisell
    World Journal of Surgery, 1998, 22 : 605 - 612
  • [32] Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells
    De Martino, Maria Cristina
    van Koetsveld, Peter M.
    Feelders, Richard A.
    Lamberts, Steven W. J.
    de Herder, Wouter W.
    Colao, Annamaria
    Pivonello, Rosario
    Hofland, Leo J.
    ENDOCRINE, 2016, 52 (03) : 664 - 667
  • [33] Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma
    Kroiss, Matthias
    Plonne, Dietmar
    Kendl, Sabine
    Schirmer, Diana
    Ronchi, Cristina L.
    Schirbel, Andreas
    Zink, Martina
    Lapa, Constantin
    Klinker, Hartwig
    Fassnacht, Martin
    Heinz, Werner
    Sbiera, Silviu
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 174 (03) : 343 - 353
  • [34] Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma
    Zhuang, Jintao
    Wang, Daohu
    Wu, Rongpei
    Tu, Xiangan
    Chen, Yu
    Qiu, Shaopeng
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (11) : 1079 - 1081
  • [35] OPTIMAL TREATMENT OF ADRENOCORTICAL CARCINOMA WITH MITOTANE - RESULTS IN A CONSECUTIVE SERIES OF 96 PATIENTS
    HAAK, HR
    HERMANS, J
    VANDEVELDE, CJH
    LENTJES, EGWM
    GOSLINGS, BM
    FLEUREN, GJ
    KRANS, HMJ
    BRITISH JOURNAL OF CANCER, 1994, 69 (05) : 947 - 951
  • [36] Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
    Puglisi, Soraya
    Calabrese, Anna
    Basile, Vittoria
    Ceccato, Filippo
    Scaroni, Carla
    Simeoli, Chiara
    Torlontano, Massimo
    Cannavo, Salvatore
    Arnaldi, Giorgio
    Stigliano, Antonio
    Malandrino, Pasqualino
    Saba, Laura
    Altieri, Barbara
    Della Casa, Silvia
    Perotti, Paola
    Berchialla, Paola
    De Filpo, Giuseppina
    Canu, Letizia
    Loli, Paola
    Reimondo, Giuseppe
    Terzolo, Massimo
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [37] Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy
    Altieri, Barbara
    Lalli, Enzo
    Faggiano, Antongiulio
    MINERVA ENDOCRINOLOGY, 2022, 47 (02): : 203 - 214
  • [38] Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma
    Dojcinovic, Tamara
    Tomsic, Karin Zibar
    Vodanovic, Ivana Dora
    Dusek, Tina
    Kraljevic, Ivana
    Nekic, Anja Barac
    Polovina, Tanja Skoric
    Knezevic, Nikola
    Alduk, Ana Marija
    Golubic, Zrna Antunac
    Kastelan, Darko
    ENDOCRINE RESEARCH, 2024,
  • [39] The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
    van Koetsveld, Peter M.
    Creemers, Sara G.
    Dogan, Fadime
    Franssen, Gaston J. H.
    de Herder, Wouter W.
    Feelders, Richard A.
    Hofland, Leo J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (02): : 407 - 417
  • [40] Correction to: Mitotane in adrenocortical carcinoma: a profile of its use
    Matt Shirley
    Drugs & Therapy Perspectives, 2023, 39 : 222 - 222